


Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. – 9. (Canceled).

10. (Currently Amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R^1 represents $-C_{2-7}$ alkyl or $-(CH_2)_m-C_{3-7}$ cycloalkyl;

R^2 represents ~~$X-C_{3-8}$ cycloalkyl, X -aryl, X -heteroaryl, X -heterocyclyl, $X-C_{3-8}$ cycloalkyl-Y- C_{3-8} cycloalkyl, $X-C_{3-8}$ cycloalkyl-Y-aryl, $X-C_{3-8}$ cycloalkyl-Y-heteroaryl, $X-C_{3-8}$ cycloalkyl-Y-heterocyclyl, X -aryl-Y- C_{3-8} cycloalkyl, X -aryl-Y-aryl, X -aryl-Y-heteroaryl, X -aryl-Y-heterocyclyl, X -heteroaryl-Y- C_{3-8} cycloalkyl, X -heteroaryl-Y-aryl, X -heteroaryl-Y-heteroaryl, X -heteroaryl-Y-heterocyclyl, X -heterocyclyl-Z-aryl, X -heterocyclyl-Y- C_{3-8} cycloalkyl, X -heterocyclyl-Y-heteroaryl or X -heterocyclyl-W-heterocyclyl~~ $-X$ -heteroaryl optionally substituted by a $-CONR^5R^6$ group, such that R^2 is linked to O via a carbon atom;

~~W represents a bond, C_{4-6} alkyl, CO, COC_{2-6} alkenyl, O or SO_2 ;~~

X represents a bond or C_{1-6} alkyl;

~~Y represents a bond, C_{4-6} alkyl, CO, COC_{2-6} alkenyl, O or SO_2 ;~~

~~Z represents a bond, CO, COC_{2-6} alkenyl, O or SO_2 ;~~

R^3 represents halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino or trifluoromethyl;

m represents an integer from 1-3;

n is 0, 1 or 2;

wherein said alkyl groups of R¹ may be optionally substituted by one or more substituents which may be the same or different and which are selected from the group consisting of halogen, cyano, C₁₋₆ alkyl, C₁₋₆ alkoxy, haloC₁₋₆ alkyl and haloC₁₋₆ alkoxy;

~~wherein said cycloalkyl, aryl, heteroaryl and heterocyclyl groups of R² may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, =O, trifluoromethyl, trifluoromethoxy, fluoromethoxy, difluoromethoxy, C₁₋₆ alkyl, pentafluoroethyl, C₁₋₆ alkoxy, arylC₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkoxyC₁₋₆ alkyl, C₃₋₇ cycloalkylC₁₋₆ alkoxy, C₁₋₆ alkanoyl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyloxy, C₁₋₆ alkylsulfonylC₁₋₆ alkyl, sulfonyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC₁₋₆ alkyl, aryloxy, C₁₋₆ alkylsulfonamido, C₁₋₆ alkylamino, C₁₋₆ alkylamido, R⁴, CO₂R⁴, COR⁴, C₁₋₆ alkylsulfonamidoC₁₋₆ alkyl, C₁₋₆ alkylamidoC₁₋₆ alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC₁₋₆ alkyl, arylcarboxamidoC₁₋₆ alkyl, aroyl, aroylC₁₋₆ alkyl, arylC₁₋₆ alkanoyl, or a group NR⁵R⁶, C₁₋₆ alkylNR⁵R⁶, C₃₋₈ cycloalkylNR⁵R⁶, CONR⁵R⁶, NR⁵COR⁶, NR⁵SO₂R⁶, OCONR⁵R⁶, NR⁵CO₂R⁶, NR⁴CONR⁵R⁶ and SO₂NR⁵R⁶, wherein R⁴, R⁵ and R⁶ independently represent hydrogen, C₁₋₆ alkyl, -C₃₋₈ cycloalkyl, -C₁₋₆ alkyl-C₃₋₈ cycloalkyl, aryl, heterocyclyl or heteroaryl or wherein NR⁵R⁶ may represent a nitrogen-containing heterocyclyl group, wherein said R⁴, R⁵ and R⁶ groups may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, cyano, amino, =O and trifluoromethyl; with the proviso that a compound of formula (I) is not 3-cyclopropylmethyl 7-(1-isopropyl piperidin-4-yloxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine.~~

11. (Currently Amended) A compound as defined in claim 10 which is selected from the group consisting of:

1-(5-{[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-2-pyrazinyl)-2-pyrrolidinone;

3-(1-methylethyl)-7-[(phenylmethyl)oxy]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

3-(2-methylpropyl)-7-[(phenylmethyl)oxy]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

3-Ethyl-7-[(phenylmethyl)oxy]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

3-(cyclopropylmethyl)-7-[(4-piperidinylmethyl)oxy]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

4-{[4-({[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}methyl)-1-piperidinyl]carbonyl}benzonitrile;

3-(cyclopropylmethyl)-7-[(1-[(4-fluorophenyl)carbonyl]-4-piperidinyl)methyl]oxy]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

7-({[1-(cyclopropylcarbonyl)-4-piperidinyl]methyl}oxy)-3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

3-(cyclopropylmethyl)-7-({[1-(tetrahydro-2*H*-pyran-4-ylcarbonyl)-4-piperidinyl]methyl}oxy)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

1-(6-{[3-(1-methylethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-3-pyridinyl)-2-pyrrolidinone;

1-(6-{[3-(2-methylpropyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-3-pyridinyl)-2-pyrrolidinone;

1-(6-{[3-(2,2-dimethylpropyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-3-pyridinyl)-2-pyrrolidinone;

1-(6-{[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-3-pyridinyl)-2-pyrrolidinone;

1-{6-[(3-ethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone;

1-(6-{[3-(1-methylpropyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-3-pyridinyl)-2-pyrrolidinone;

1-(6-{[3-(cyclobutylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-3-pyridinyl)-2-pyrrolidinone;

3-(cyclopropylmethyl)-7-[[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyridinyl]oxy]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

1-(4-[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}phenyl)-3-methyl-2-imidazolidinone;

3-(cyclopropylmethyl)-7-[(phenylmethyl)oxy]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

7-[(3-cyclohexylpropyl)oxy]-3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

3-(cyclopropylmethyl)-7-(phenyloxy)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

Ethyl 4-[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}benzoate;

~~6-[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-*N*-methyl-3-pyridinecarboxamide;~~

~~5-[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-*N*-methyl-2-pyrazinecarboxamide;~~

1,1-dimethylethyl 4-[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-1-piperidinecarboxylate;

3-(cyclopropylmethyl)-7-(4-piperidinyloxy)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

4-[(4-[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-1-piperidinyl)carbonyl]benzonitrile;

1-(5-[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-2-pyridinyl)-2-pyrrolidinone;

1-(5-[[3-(2-methylpropyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-2-pyridinyl)-2-pyrrolidinone;

1-(5-[[3-(1-methylethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-2-pyridinyl)-2-pyrrolidinone;

1,1-dimethylethyl 4-([3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy)methyl)-1-piperidinecarboxylate;

3-(cyclopropylmethyl)-7-[(4-iodophenyl)oxy]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;


or a pharmaceutically acceptable salt thereof.

12. (Previously Amended) A pharmaceutical composition which comprises the compound of claim 10 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

13. (Previously Amended) A method of treatment of neurological diseases which comprises administering to a human in need thereof an effective amount of a compound claim 10 or a pharmaceutically acceptable salt thereof, wherein said neurological disease is selected Alzheimer's disease, age-related memory dysfunction, and mild cognitive impairment.

14. (Previously Amended) A process for the preparation of a compound of Claim 10 or a pharmaceutically acceptable salt thereof, which process comprises:


(a) reacting a compound of formula (II)



(II)

wherein R^1 , R^3 and n are as defined in claim 10, with a compound of formula $R^{2'}$ - L^1 , wherein $R^{2'}$ is as defined in claim 10 for R^2 or a group convertible thereto and L^1 represents a suitable leaving group;

(b) reacting a compound of formula (III)



(III)

wherein R^2 , R^3 and n are as defined in claim 10, with a compound of formula $R^{1'}$ - L^2 , wherein $R^{1'}$ is as defined in claim 10 for R^1 or a group convertible thereto and L^2 represents a suitable leaving group; or

(c) reacting a compound of formula (III) as defined above, with a ketone of formula $R^{1''}=O$, wherein $R^{1''}$ is $=C_{2-7}$ alkyl or $=(CH_2)_m-C_{3-7}$ cycloalkyl or a group convertible thereto; or

(d) deprotecting a compound of formula (I) which is protected; or

(e) interconversion from one compound of formula (I) to another.

15. (New) The compound according to claim 10 or a pharmaceutically acceptable salt thereof wherein R^2 represents pyridinyl or pyrazinyl optionally substituted by $CON(H)Me$.

16. (New) The compound according to claim 10 or a pharmaceutically acceptable salt thereof selected from the group consisting of

6- $\{[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy\}$ -*N*-methyl-3-pyridinecarboxamide and

5- $\{[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy\}$ -*N*-methyl-2-pyrazinecarboxamide.